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ABSTRACT
Acute pulmonary embolisms is a major 
cause of complications and death associated in 
surgery, medical illnesses, injury, and also may 
occurs after  a long-distance air travel. It is often 
originating from deep-vein thrombosis and has a 
wide spectrum of clinical manifestation ranging 
from asymptomatic, incidentally discovered emboli, 
to massive embolism causing immediate death. 
Incidence of pulmonary embolism ranges from 23-
69 cases per 100,000 populations. Case fatality 
rates vary widely depending on the severity of the 
cases; at an average case fatality rate within 2 week 
of diagnosis of approximately 11%. It may have 
chronic sequele as post thrombotic syndrome and 
chronic thromboembolism pulmonary hypertension.
Acute pulmonary embolism is often difficult 
to diagnose. The predisposing factors for pulmonary 
embolisms consist of hereditary factors, acquired 
factors, and probable factors. Patients with 
symptoms of dyspnea, chest apnea, tachypnea or 
tachycardia arise suspiciousness of pulmonary 
embolisms therefore should be screened their 
probability for developing the disease. Low risk 
patients will then be evaluated for d-dimer test. 
Treatment should be initiated promptly in high risk 
patients, followed by imaging procedure evaluation. 
Chest radiographs, CT scan arteriography, VQ scan 
are performed to either include or exclude diagnosis 
of pulmonary embolisms.
Treatments consist of thrombolysis for acute 
and unstable massive pulmonary embolisms, and 
anticoagulation with heparin for stable acute 
pulmonary embolism. A meta-analysis of several 
major trials showed that low molecular weight 
heparin is at least as effective as unfractionated 
heparin in preventing the recurrence of venous 
thromboembolism events and at least as safe with 
respect to the rate of major bleeding.
This review will further describe in detail 
the pathomechanisms, diagnosis, and management 
of acute pulmonary embolisms.
INTRODUCTION
Pulmonary  embol isms (PE)  i s  a  
cardiovascular and cardiopulmonary symptoms 
caused by oclusion of the main pulmonary vessels 
by embolic process. Embolism is originated from 
detachment of thrombus – ussually from deep vein 
1,2  thrombosis- and then propagated . Pulmonary 
embolisms (PE) and deep vein thrombosis (DVT) is 
one spectrum of disease. About 79% of patients with 
PE have DVT in their legs and 50 % of patients with 
3DVT will progress to PE .
In US incidence of PE reaches 1 per 1000 
population; with 15 % mortality within 3 month of 
diagnosis. Mortality due to PE reaches 300,000 
cases per year that make it as deadly as acute 
3coronory syndrome . 
Eventhough in some certain countries 
incidence of venous thromboembolisms is not  
frequent, awareness of it should be routinely 
performed especially for highrisk groups of patients 
4.
Diagnosing PE is not easy. Lack of 
awareness and non specific symptoms and signs of 
PE make it difficult to diagnose at early course of 
disease and many of  PE are diagnosed post 
mortemly.
This review is aimed at describing clinical 
manifestations of pulmonary embolisms, its 
pathomechanisms, diagnostic procedures, and 
management based on the most recent literatures and 
publications.
Pathophysiology
Thrombi arises from deep veins in the lower 
extremity, propagate in the proximal veins include 
popliteal veins and their upper veins, in which is 
3easier to form embolization . Emboli migrates from 
right ventricle and plugs pulmonary arterial.  
In acute PE, anatomical obstruction will 
decrease pulmonary function, followed by secretion 
of vasoactive and bronchoactive mediators that lead 
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to impairment of ventilation-perfusion. Increasing 
of right ventricle wall pressure cause ventricle 
dilatation, dysfunction, and ischemic of right 
ventricle. Death may caused by right ventricular 
3failure .
Risk Factors
Many health's condition and genetic factors 
increase the risk of PE. All risk factors of DVT 
become risk factors of PE. Table 1  gives summary 
of the risk factors of PE including hereditary and 
acquired risk factors.
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Table 1. Risk Factors of Venous 
Thromboembolisms (Deep Vein Thrombosis 
3,5and Pulmonary Embolisms)
Diagnosis approach
Symptoms of PE are not specific. Dyspneu, 
tachycardia, pleuritic pain, and hemoptysis are 
sometimes found in patients with PE as well as other 
diseases. Cough, palpitation, light headedness, 
fever, and rales are common symptoms and signs 
which may be obscured by presenting  comorbid 
illness. Symptoms and signs of pulmonary 
hypertension like elevation of jugular vein pressure, 
loud P2, gallops on the right ventricle, and elevation 
of right heart configuration may rise suspicion to PE 
b u t  n e i t h e r   s e n s i t i v e  n o r  s p e c i f i c .  
Electrocardiography showed unexplained sinus 
tachycardia, and S1Q3T3 pattern in massive 
pulmonary embolisms, right bundle branch block, P 
pulmonale, and right axis deviation.  
Patient with PE usually present with 
hypoxemia, but somehow blood gas analysis 
showed normal results in large number of patients. 
Cyanosis, hypotension, and syncope may preceed a 
2,6,7  fatal and massive PE that lead to death . Troponin 
may increase in PE but should not be used as 
diagnosis marker; its indication is recommended for 
8prognostic stratification .
Upon suspicion of PE, physician should 
perform a comprehensive and detailed anamnesis, 
assessment of prediction probability of PE and its 
risk factors, biomarker test and diagnostic imaging. 
A  s i m p l e  m e t h o d  t o  p r e d i c t  
thromboembolism is developed by Wells et al using 
Clinical Prediction Rules for Pulmonary 
9,10,11Embolism . Beside Wells criteria, it has been 
developed other prediction criteria using more 
complicated items, radiographic imaging, and 
electrocardiography that should be interpreted by an 
1,5,12expert .
Tabel 2. Wells Clinical Prediction Rule 
9for Pulmonary Embolism (PE)
Clinical feature  PointsClinical symptoms of DVT
 
3
Other diagnosis less likely than PE 3
Heart rate greater than 100 beats per minute 1.5
Immobilization or surgery within past 4 weeks 1.5
Previous DVT or PE 1.5
Hemoptysis 1
Malignancy 1
Total points 12.5
Risk score interpretation (probability of PE):  
>6 points: high risk (78.4%);  
2 to 6 points: moderate risk (27.8%);  
<2 points: low risk (3.4%).
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Diagnostic Imaging
Patients with low probability of PE at 
outpatient setting should undergo D-Dimer test. D-
dimer is a method to measure degradation product of 
cross linked-fibrin in the blood circulation. This 
method has a high sensitivity value but low 
specificity. Increasing of D-dimer is  almost always 
happened in patients with emboli, as well as in 
elderly, trauma, post surgery, pregnancy, 
inflammation, and  cancer.  In patients with low risk 
probability and high D-Dimer results using highly 
sensitive D-Dimer assay should be followed by 
12imaging diagnostic procedures . In publication by 
Gibson et al D-Dimer test should be performed after 
clinical probability assessment or clinical prediction 
rule has done. High clinical probability patients 
should undergo other testing, regardless the D-
12,20Dimer outcome .
Treatment should be initiated promptly for 
high risk probability patients, while concommitantly 
carrying out diagnostic procedures such as helical 
CT scanning, ventilation-perfusion scanning, 
pulmonary arteriography until diagnosis is 
12established . Ventilation-perfusion scanning has the 
important role in diagnosing PE for almost 3 
decades. Positive results from ventilation-perfusion 
scanning (V/Q scanning) gives high sensitivity for 
thromboembolism. However many large trial 
showed patients with emboli showed normal 
12ventilation-perfusion scanning .
Computed Tomography scanning has 
superiority compared with ventilation-perfusion 
scanning in term of either sensitivity or specificity.  
Helical CT scan has 57-100% sensitivity and 78-
100% specificity. If the helical CT showed negative 
for PE, the likelihood of PE diagnosis is low, but can 
not directly exclude PE diagnosis as well as 
12ventilation perfusion scanning . A negative result of 
multidetector-row CT can safely rule out PE 
12,27diagnosis .
12Figure.1 Diagnostic approachs of pulmonary embolism
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Evaluation of veins in lower extremities should 
always be performed as PE arise from DVT. Duplex 
USG will be positive in 10-20% patients without 
symptoms in their leg, and USG of lower 
extremities' veins will positive in 50% patients with 
emboli. Normal USG duplex does not exclude 
12diagnosis of emboli .
Gold standard in PE diagnosis is pulmonary 
angiography. This invasive procedure needs 
specialistic technique and expert interpreter. 
Pulmonary angiography should be performed in 
condition where other non invasive diagnostic 
12procedures are not conclusive .
Treatment
Upon established diagnosis, patient with PE 
should be hospitalized and resting for the first 48 
3hours . If there were no contraindications, 
anticoagulation with heparin or low molecular 
weight heparin should be instituted. Survival will be 
improved with anticoagulation but recurrence rate is 
3still 5-10% within 1 year post diagnosis . Warfarin 
should be given concurrently with heparin at the first 
day of treatment.  Minimal duration of 
3anticoagulation is 5-days .Low molecular weight 
heparins have the similar efficacy as unfractionated 
heparin and have some advantages over it in term of: 
higher bioavailability, more predictable dose, 
heparin and have some advantages over it in term of: 
higher bioavailability, more predictable dose, 
convenient in usage, no need for monitoring, and 
f e w e r  i n c i d e n c e  o f  h e m o r r h a g e  a n d  
3,18,23thrombocytopenia .
Direct thrombin inhibitor is indicated for 
t h r o m b o o s i s  a n d  h e p a r i n - i n d u c e d  
th rombocytopenia .  Inh ib i to r  fac tor  Xa  
(rivuroxaban, apixaban, idraparinux and aptamers) 
3,15are still in phase 3 trial for PE .
Massive PE needs more aggresive 
treatment. Sodium chloride infusion, vasopressor, 
oxygenation, and intubation should be initiated in 
16cardiorespiratory failure .
Thrombolytic is indicated in PE presenting 
with cardiogenic shock, or systemic hypotension. In 
sub massive PE without shock thrombolytic 
treatment is still debatable. No significant difference 
between thrombolytic therapy and  heparinization in 
17PE, unless in severe and acute PE .
In massive, acute PE in which thrombolytic 
therapy is contraindicated, mechanical pulmonary 
3embolectomy should be performed .
1,23Table 3. Initial treatment for PE management
Drug  Mode of Administration
 
Note
Unfractionated heparin
 (intravenous infusion)
 
80U/kg
 
BW bolus iv 
continued with 18 IU/kg 
BW
 
/hours
 
continous 
infusion
 
Adjust the rate to achieve
aPTT 1.5 -2.5 times control 
monitor thrombocyte every 2 
days starting from day -4 up to 
da-14 or untill heparin is 
stopped. Aware of HIT if 
thrombocyte count decrease 
more than 50% OR developed 
thrombosis18
Low molecular weight heparin
 
(LMWH)
 
LMWH is not recommended 
for PE with hypotension or 
shock
          
enoxaparin
 
1.0 mg/kg
 
BW every 12 
hours sc or 1.5 mg/kg
 
BW once daily
If creatinin clearance <30 
ml/minute reduce dose to 
1 mg/kg BW/day or substitute 
with UFH
fondaparinux 5 mg for body weight < 
50 kg and 7.5 mg for 
body weight 50 kg-100 
kg and 10 mg for body 
weight > 100 kg
Contraindicated for creatinin
clearance < 30 ml
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Prognosis
Almost all patient with PE will survive after 
received adequate anticoagulation. Overall 
mortality rate within 3 months after  diagnosis is 15-
18%. Survival is determined by present or abscence 
of syncope or shock in the first hours of PE onset. 
Post  thrombotic syndrome and chronic 
thromboembolic pulmonary hypertension is a 
19,25common sequalae of PE .
Recurrency is still a major problem in acute 
PE. Recurrent VTE is found among 17.6% patients 
with symptomatic PE and among 9.5% patients  
DVT without symptomatic PE. Relative risk for 
recurrence VTE in PE is 2.2 (95% confident interval 
21  1.3-3.7,p=0.005) . Predictors of recurrence in 
thrombosis are unprovoked VTE, thrombophillia, 
primary DVT, shorter episode of anticoagulation 
22,24(up to 6 months), and elderly . Persistent right 
ventricular dysfunction at hospital discharge from 
first episode of PE is also associated with right 
26ventricular dysfunction . Nomogram for predicting 
recurrency in unprovoked VTE has been developed 
by scoring sex, location of VTE, and d-Dimer 
28results .
SUMMARY
Physicians should aware of pulmonary 
embolism. Diagnosing PE is not always easy. 
Patients with unexplained dyspneu, tachycardia, 
hemoptisis, with or without deep vein thrombosis 
should be assessed probability of PE with clinical 
probability test developed by Wells. Those with 
high and moderate probability should be initiated 
treatment while waiting further test. Higher d-dimer 
value directs to chest x ray and multidetector chest 
CT. If PE was detected by imaging, anticoagulation 
is continued for up to 6 month. Unprovoked VTE 
needs lifelong anticoagulation.
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